脑胶质瘤患者血清IGFBP2、miR-29c水平变化及其临床意义

doi:10.3969/j.issn.1671-7171.2019.05.011

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】To investigate the changes of serum insulin-like growth factor binding protein 2 (IGFBP2) and microRNA-29c (miR-29c) levels in patients with glioma and their clinical significance. 【Methods】Eighty patients with glioma diagnosed in our hospital from January 2016 to December 2017 (case group), 80 healthy subjects with age, gender and case group were selected as the control group, and the serum of the two groups were tested. IGFBP2 and miR-29c levels were analyzed by stratification according to tumor diameter, pathological type, WHO classification, and tumor location. 【Results】The level of serum IGFBP2 in the observation group was significantly higher than that in the control group, and the level of serum microRNA-29c was significantly lower than that in the control group, with statistical significance (P<0.05). The serum levels of IGFBP2 and microRNA-29c in patients with WHO grade Ⅲ were significantly higher than those in patients with WHO grade Ⅰ and Ⅱ, while the serum levels of microRNA-29c were significantly lower than those in patients with WHO grade Ⅰ and Ⅱ (P<0.05); there was no significant difference in serum levels of IGFBP2 and microRNA-29c between patients with different pathological types, lesion diameters and tumor sites (P>0.05). 【Conclusion】The level of serum IGFBP2 increases and the expression of microRNA-29c decreases in glioma patients, which is correlated with the grade of glioma.

Key words： Glioma Insulin-Like Growth Factor Binding Protein 2 MicroRNAs

Received: 26 September 2018

PACS:

R730.264

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2019.05.011 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2019/V36/I5/866

[1] Arun S, Vanisree AJ, Ravisankar S. Connexin 30 downregulates Insulin-like growth factor receptor-1, abolishes Erk and potentiates effects of an IGF-R inhibitor in a glioma cell line[J].Brain Res,2016,1643(6):80-90.
[2] 叶昀,牛朝诗,杨洋,等. 胶质瘤中IGF-1和IGFBP-3的表达及临床意义研究[J].安徽医科大学学报,2016,51(2):231-234.
[3] 闫改军,葛云飞,胡群亮,等. 长链非编码RNA在胶质瘤中的作用机制[J].武警后勤学院学报(医学版),2016,25(11):942-944.
[4] 邓裕佳,卢明,滕晓华. 胰岛素样生长因子结合蛋白-2与胶质瘤的研究进展[J].国际神经病学神经外科学杂志,2017,44(2):217-220.
[5] Kosteniuk SE, Gui C, Gariscsak PJ,et al.The Impact of Functional Magnetic Resonance Imaging on Clinical Outcomes in a Propensity-Matched Low Grade Glioma Cohort[J].World Neurosurg,2018,35(6):103-106.
[6] 王瑞,张守丹,孙大鹏. 胰岛素样生长因子结合蛋白-3在白藜芦醇抑制脑胶质瘤C6细胞增殖中的作用[J].中国生物制品学杂志,2015,28(8):795-799.
[7] 梁之孔,王玉梁,李辉,等. 长链非编码RNA与多梳家族蛋白在神经胶质瘤中相互作用的研究进展[J].武警后勤学院学报(医学版),2017,26(5):457-460.
[8] 王行健,朱淑霞. 长链非编码RNA与人脑胶质瘤关联性的研究进展[J].中国当代医药,2018,25(6):21-24.
[9] 薛贵生,扈玉华,吴建梁,等. 不同级别恶性脑胶质瘤中胰岛素样生长因子结合蛋白-3的表达差异[J].中华实验外科杂志,2015,32(5):1069-1071.
[10] 王文斐,刘文庆,宋祖耀,等. 胶质瘤组织及血清中胰岛素样生长因子-2的表达和意义[J].中国微侵袭神经外科杂志,2015,20(5):227-230.
[11] 陈峰,骆纯. 长链非编码RNA在脑胶质瘤发病及进展中功能作用的研究进展[J].中国微侵袭神经外科杂志,2016,21(7):328-330.
[12] 李爱林,王金环. MicroRNA在胶质瘤形成及靶向治疗中的作用[J].中国微侵袭神经外科杂志,2015,20(8):379-381.